risks of taking tirzepatide Long-Term Safety Tirzepatide: What Research and Experts Reveal Tirzepatide: How It's Used &

Temporary shifts in digestive habits, including passing heartburn, bloating, mild constipation, or brief periods of loose stools

Tirzepatide and injectable semaglutide were associated with the greatest weight loss after a year of treatment among several GLP-1 receptor agonists, a recent study showed.“Despite being the most recent medication approved for weight loss, tirzepatide [Zepbound, Eli Lilly] showed the greatest weight loss among the GLP-1 medications studied,&rdquo

Energy regulation and metabolic signaling environments

Adverse events were mostly mild to moderate in severity, with the most common being gastrointestinal events including nausea, diarrhoea, decreased appetite and vomiting

Subgroup analysis for treatment durations6 months indicated a higher WL in the GLP-1RAs group (SMD=0.79, 95% CI 0.25 to 1.34)